Report Detail

Pharma & Healthcare Global EGFR Inhibitors for Lung Cancer Market Growth 2022-2028

  • RnM4495459
  • |
  • 23 November, 2022
  • |
  • Global
  • |
  • 118 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

The global market for EGFR Inhibitors for Lung Cancer is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key EGFR Inhibitors for Lung Cancer players cover Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global EGFR Inhibitors for Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global EGFR Inhibitors for Lung Cancer market, with both quantitative and qualitative data, to help readers understand how the EGFR Inhibitors for Lung Cancer market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the EGFR Inhibitors for Lung Cancer market and forecasts the market size by Type (Geftinib, Afatinib and Osimertinib), by Application (Medical Care, Experiment and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Geftinib
Afatinib
Osimertinib
Other

Segmentation by application
Medical Care
Experiment
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Pfizer
AstraZeneca
Genentech (Roche Group)
Beta Pharma
Mylan
Boehringer Ingelheim
Teva Pharmaceuticals
Qilu Pharmaceutical
Betta Pharmaceuticals
Haosen Pharmaceutical
ARIAD Pharmaceuticals
HUTCHMED
Shanghai Ellis
Genvio Pharma
Everest Pharmaceuticals
Incepta Pharmaceuticals
Jiangsu Hengrui Medicine

Chapter Introduction
Chapter 1: Scope of EGFR Inhibitors for Lung Cancer, Research Methodology, etc.
Chapter 2: Executive Summary, global EGFR Inhibitors for Lung Cancer market size (sales and revenue) and CAGR, EGFR Inhibitors for Lung Cancer market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: EGFR Inhibitors for Lung Cancer sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global EGFR Inhibitors for Lung Cancer sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global EGFR Inhibitors for Lung Cancer market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma, Mylan, Boehringer Ingelheim, Teva Pharmaceuticals, Qilu Pharmaceutical and Betta Pharmaceuticals, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Country/Region, 2017, 2022 & 2028
  • 2.2 EGFR Inhibitors for Lung Cancer Segment by Type
    • 2.2.1 Geftinib
    • 2.2.2 Afatinib
    • 2.2.3 Osimertinib
    • 2.2.4 Other
  • 2.3 EGFR Inhibitors for Lung Cancer Sales by Type
    • 2.3.1 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
    • 2.3.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Type (2017-2022)
  • 2.4 EGFR Inhibitors for Lung Cancer Segment by Application
    • 2.4.1 Medical Care
    • 2.4.2 Experiment
    • 2.4.3 Others
  • 2.5 EGFR Inhibitors for Lung Cancer Sales by Application
    • 2.5.1 Global EGFR Inhibitors for Lung Cancer Sale Market Share by Application (2017-2022)
    • 2.5.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Application (2017-2022)

3 Global EGFR Inhibitors for Lung Cancer by Company

  • 3.1 Global EGFR Inhibitors for Lung Cancer Breakdown Data by Company
    • 3.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Company (2020-2022)
    • 3.1.2 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Company (2020-2022)
  • 3.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Company (2020-2022)
    • 3.2.1 Global EGFR Inhibitors for Lung Cancer Revenue by Company (2020-2022)
    • 3.2.2 Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company (2020-2022)
  • 3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Company
  • 3.4 Key Manufacturers EGFR Inhibitors for Lung Cancer Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers EGFR Inhibitors for Lung Cancer Product Location Distribution
    • 3.4.2 Players EGFR Inhibitors for Lung Cancer Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for EGFR Inhibitors for Lung Cancer by Geographic Region

  • 4.1 World Historic EGFR Inhibitors for Lung Cancer Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Geographic Region
  • 4.2 World Historic EGFR Inhibitors for Lung Cancer Market Size by Country/Region (2017-2022)
    • 4.2.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Country/Region
  • 4.3 Americas EGFR Inhibitors for Lung Cancer Sales Growth
  • 4.4 APAC EGFR Inhibitors for Lung Cancer Sales Growth
  • 4.5 Europe EGFR Inhibitors for Lung Cancer Sales Growth
  • 4.6 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Growth

5 Americas

  • 5.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country
    • 5.1.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
    • 5.1.2 Americas EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
  • 5.2 Americas EGFR Inhibitors for Lung Cancer Sales by Type
  • 5.3 Americas EGFR Inhibitors for Lung Cancer Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region
    • 6.1.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region (2017-2022)
    • 6.1.2 APAC EGFR Inhibitors for Lung Cancer Revenue by Region (2017-2022)
  • 6.2 APAC EGFR Inhibitors for Lung Cancer Sales by Type
  • 6.3 APAC EGFR Inhibitors for Lung Cancer Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe EGFR Inhibitors for Lung Cancer by Country
    • 7.1.1 Europe EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
    • 7.1.2 Europe EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
  • 7.2 Europe EGFR Inhibitors for Lung Cancer Sales by Type
  • 7.3 Europe EGFR Inhibitors for Lung Cancer Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa EGFR Inhibitors for Lung Cancer by Country
    • 8.1.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Type
  • 8.3 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of EGFR Inhibitors for Lung Cancer
  • 10.3 Manufacturing Process Analysis of EGFR Inhibitors for Lung Cancer
  • 10.4 Industry Chain Structure of EGFR Inhibitors for Lung Cancer

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 EGFR Inhibitors for Lung Cancer Distributors
  • 11.3 EGFR Inhibitors for Lung Cancer Customer

12 World Forecast Review for EGFR Inhibitors for Lung Cancer by Geographic Region

  • 12.1 Global EGFR Inhibitors for Lung Cancer Market Size Forecast by Region
    • 12.1.1 Global EGFR Inhibitors for Lung Cancer Forecast by Region (2023-2028)
    • 12.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global EGFR Inhibitors for Lung Cancer Forecast by Type
  • 12.7 Global EGFR Inhibitors for Lung Cancer Forecast by Application

13 Key Players Analysis

  • 13.1 Pfizer
    • 13.1.1 Pfizer Company Information
    • 13.1.2 Pfizer EGFR Inhibitors for Lung Cancer Product Offered
    • 13.1.3 Pfizer EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Pfizer Main Business Overview
    • 13.1.5 Pfizer Latest Developments
  • 13.2 AstraZeneca
    • 13.2.1 AstraZeneca Company Information
    • 13.2.2 AstraZeneca EGFR Inhibitors for Lung Cancer Product Offered
    • 13.2.3 AstraZeneca EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 AstraZeneca Main Business Overview
    • 13.2.5 AstraZeneca Latest Developments
  • 13.3 Genentech (Roche Group)
    • 13.3.1 Genentech (Roche Group) Company Information
    • 13.3.2 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product Offered
    • 13.3.3 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Genentech (Roche Group) Main Business Overview
    • 13.3.5 Genentech (Roche Group) Latest Developments
  • 13.4 Beta Pharma
    • 13.4.1 Beta Pharma Company Information
    • 13.4.2 Beta Pharma EGFR Inhibitors for Lung Cancer Product Offered
    • 13.4.3 Beta Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Beta Pharma Main Business Overview
    • 13.4.5 Beta Pharma Latest Developments
  • 13.5 Mylan
    • 13.5.1 Mylan Company Information
    • 13.5.2 Mylan EGFR Inhibitors for Lung Cancer Product Offered
    • 13.5.3 Mylan EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Mylan Main Business Overview
    • 13.5.5 Mylan Latest Developments
  • 13.6 Boehringer Ingelheim
    • 13.6.1 Boehringer Ingelheim Company Information
    • 13.6.2 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product Offered
    • 13.6.3 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Boehringer Ingelheim Main Business Overview
    • 13.6.5 Boehringer Ingelheim Latest Developments
  • 13.7 Teva Pharmaceuticals
    • 13.7.1 Teva Pharmaceuticals Company Information
    • 13.7.2 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
    • 13.7.3 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Teva Pharmaceuticals Main Business Overview
    • 13.7.5 Teva Pharmaceuticals Latest Developments
  • 13.8 Qilu Pharmaceutical
    • 13.8.1 Qilu Pharmaceutical Company Information
    • 13.8.2 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
    • 13.8.3 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Qilu Pharmaceutical Main Business Overview
    • 13.8.5 Qilu Pharmaceutical Latest Developments
  • 13.9 Betta Pharmaceuticals
    • 13.9.1 Betta Pharmaceuticals Company Information
    • 13.9.2 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
    • 13.9.3 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 Betta Pharmaceuticals Main Business Overview
    • 13.9.5 Betta Pharmaceuticals Latest Developments
  • 13.10 Haosen Pharmaceutical
    • 13.10.1 Haosen Pharmaceutical Company Information
    • 13.10.2 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
    • 13.10.3 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Haosen Pharmaceutical Main Business Overview
    • 13.10.5 Haosen Pharmaceutical Latest Developments
  • 13.11 ARIAD Pharmaceuticals
    • 13.11.1 ARIAD Pharmaceuticals Company Information
    • 13.11.2 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
    • 13.11.3 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 ARIAD Pharmaceuticals Main Business Overview
    • 13.11.5 ARIAD Pharmaceuticals Latest Developments
  • 13.12 HUTCHMED
    • 13.12.1 HUTCHMED Company Information
    • 13.12.2 HUTCHMED EGFR Inhibitors for Lung Cancer Product Offered
    • 13.12.3 HUTCHMED EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 HUTCHMED Main Business Overview
    • 13.12.5 HUTCHMED Latest Developments
  • 13.13 Shanghai Ellis
    • 13.13.1 Shanghai Ellis Company Information
    • 13.13.2 Shanghai Ellis EGFR Inhibitors for Lung Cancer Product Offered
    • 13.13.3 Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.13.4 Shanghai Ellis Main Business Overview
    • 13.13.5 Shanghai Ellis Latest Developments
  • 13.14 Genvio Pharma
    • 13.14.1 Genvio Pharma Company Information
    • 13.14.2 Genvio Pharma EGFR Inhibitors for Lung Cancer Product Offered
    • 13.14.3 Genvio Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.14.4 Genvio Pharma Main Business Overview
    • 13.14.5 Genvio Pharma Latest Developments
  • 13.15 Everest Pharmaceuticals
    • 13.15.1 Everest Pharmaceuticals Company Information
    • 13.15.2 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
    • 13.15.3 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.15.4 Everest Pharmaceuticals Main Business Overview
    • 13.15.5 Everest Pharmaceuticals Latest Developments
  • 13.16 Incepta Pharmaceuticals
    • 13.16.1 Incepta Pharmaceuticals Company Information
    • 13.16.2 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
    • 13.16.3 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.16.4 Incepta Pharmaceuticals Main Business Overview
    • 13.16.5 Incepta Pharmaceuticals Latest Developments
  • 13.17 Jiangsu Hengrui Medicine
    • 13.17.1 Jiangsu Hengrui Medicine Company Information
    • 13.17.2 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product Offered
    • 13.17.3 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.17.4 Jiangsu Hengrui Medicine Main Business Overview
    • 13.17.5 Jiangsu Hengrui Medicine Latest Developments

14 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on EGFR Inhibitors for Lung Cancer. Industry analysis & Market Report on EGFR Inhibitors for Lung Cancer is a syndicated market report, published as Global EGFR Inhibitors for Lung Cancer Market Growth 2022-2028. It is complete Research Study and Industry Analysis of EGFR Inhibitors for Lung Cancer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
2,997.54
5,995.08
3,484.32
6,968.64
498,455.40
996,910.80
298,948.80
597,897.60
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report